The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC.
1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling!
2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease.
4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.
-------- Â
13:41
--------
13:41
Time to Cilta-Cel-ebrate?
The 5-year+ follow-up from CARTITUDE-1 has people asking if cilta-cel can cure multiple myeloma? We discuss this data and the broad comparison to the other BCMA-targeting CAR-T product, idi-cel and a recent comparison on plasma cell leukemia.
CARTITUDE-1 Long-Term F/U: https://doi.org/10.1200/JCO-25-00760
Cilta-cel & ide-cel in plasma cell leukemia: https://doi.org/10.1182/bloodadvances.2025016966
-------- Â
10:25
--------
10:25
RNA Vaccine Potential as a Cancer Treatment
The potential breakthrough in RNA vaccine technology has been increasingly discussed on social media. This episode looks at one promising study and its early, early results so far.
UF GBM study: https://doi.org/10.1016/j.cell.2024.04.003
RNA Treatment Vaccine Review: https://doi.org/10.1002/ctm2.1384
-------- Â
11:25
--------
11:25
Venetoclax Dosing & APOLLO
Malignant Hematology Updates:
Venetoclax dosing strategies continue to evolve
HMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640
HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914
Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723
APOLLO: https://doi.org/10.1200/JCO-25-00535
Iland APOLLO editorial: https://doi.org/10.1200/JCO-25-01496
ctDNA assessment vs. PET in Large B-Cell Lymphoma: https://doi.org/10.1200/JCO-25-01534
-------- Â
17:47
--------
17:47
Zongertinib
A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Ireland